Dalian Wanchun Brin Pharmaceutical Co., Ltd. announced that it has entered into a capital increase and shareholding agreement for a private placement of common shares for gross proceeds of CNY 100 million on August 25, 2021. The transaction will include participation from Jiangsu Hengrui Medicine Co., Ltd. As a result, the investor will own more than 2.5% stake in the company. The transaction does not need to be submitted to the investor's board of directors and shareholders' meeting for deliberation. The transaction still needs the approval of relevant government departments.